This is the authors' abstract. We don't add key points for this paper.
// Kevin Y. Guo 1, 2 , Lili Han 1, 3 , Xinyu Li 2 , Andrew V. Yang 2 , Jiaxiong Lu 2 , Shan Guan 2 , Hui Li 1 , Yang Yu 2 , Yanling Zhao 2 , Jianhua Yang 2 and Hong Zhang 1, 4 1 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 2 Texas Children’s Cancer Center, Department of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA 3 Department of Gynecology, People’s Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, Xinjiang 830001, China 4 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA Correspondence to: Hong Zhang, email: zhangh3@mskcc.org Keywords: cervical cancer; proteasome; delanzomib; doxorubicin; p53 Received: October 17, 2017 Accepted: November 28, 2017 Published: December 12, 2017 ABSTRACT Cervical cancer, the third most commonly occurring cancer, is the second leading cause of cancer related mortality among women. Aberrant ubiquitination and proteasome activity, both human papillomavirus and tumor derived, have been shown to contribute to tumor angiogenesis, proliferation, and invasion in many cancers, including cervical cancer. Thus, small molecule proteasome inhibitors are a potential and strategic treatment option for cervical cancer. In this study, novel proteasome inhibitor delanzomib (CEP-18770) exhibited potent pro-apoptotic and cytotoxic effects on a panel of cervical cancer cell lines by blocking proteasomal activity. Delanzomib also significantly sensitized cervical cancer cells to treatment of doxorubicin (Dox), a traditional chemotherapeutic agent. Furthermore, proteasome inhibition revealed stabilization of p53 and p53 transcriptional targets and induction of p38/JNK phosphorylation. Additionally, delanzomib worked synergistically with Dox to further upregulate p53 and its downstream targets and enhanced Dox-induced p38 phosphorylation. Our study strongly supports the 26S proteasome as a potential therapeutic target in cervical cancer and proteasome inhibition by delanzomib may be a potential treatment strategy for cervical cancer patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: